Grünenthal acquires cancer treatment Stivarga®
Aachen (ots) - - Latest step in Grünenthal’s strategy to acquire established medicines that serve clear medical needs, leverage its commercial and operational capabilities, and drive growth. - Stivarga® (regorafenib) is an established oral treatment for certain advanced cancers, including metastatic colorectal cancer, gastrointestinal stromal tumours (GIST) and hepatocellular carcinoma (liver cancer). It is approved ...
mehr